Application of siRNA against SARS in the rhesus macaque model

Methods in Molecular Biology

Volumn 442, Issue , 2008, Pages 139-158

  Tang, Qingquan ^a   Li, Baojian ^b   Woodle, Martin ^c   Lu, Patrick Y ^d  

^a Origene Technologies Inc   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c Nanotides Pharmaceuticals Inc

^d Sirnaomics Inc

Author keywords

Diffuse alveoli damage (DAD); Proinflammatory cytokines; RNA interference (RNAi); SARS coronavirus (SCV); Severe acute respiratory syndrome (SARS); Small interfering RNA (siRNA)

Indexed keywords

ANIMALIA; MACACA; MACACA MULATTA; MAMMALIA; SARS CORONAVIRUS; STRAWBERRY CRINKLE VIRUS;

EID: 84934435964     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-191-8_11     Document Type: Article

References (57)

1. Fouchier, R. A., Kuiken, T., Schutten, M., et al. (2003). Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240.
2. Kuiken, T., Fouchier, R. A., Schutten, M., et al. (2003). Newly discovered Coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362, 263-270.
3. Ksiazek, T. G., Erdman, D., Goldsmith, C. S., et al. (2003). A novel Coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966.
4. Peiris, J. S., Lai, S. T., Poon, L. L., et al. (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325.
5. Guan, Y., Zheng, B. J., He, Y. Q., et al. (2003). Isolation and characterization of viruses related to the SARS Coronavirus from animals in Southern China. Science 203, 276-278.
6. Chinese SARS Molecular Epidemiology Consortium (2004). Molecular evolution of the SARS Coronavirus during the course of the SARS epidemic in China. Science 303, 1666-1669.
7. Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., et al. (2003). Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the Coronavirus group 2 lineage. J. Mol. Biol. 331, 991-1004.
8. Marra, M. A., Jones, S. J., Astell, C. R., et al. (2003). The genome sequence of the SARS-associated Coronavirus. Science 300, 1399-1404.
9. Nicholls, J. M., Poon, L. L., Lee, K. C., et al. (2003). Lung pathology of fatal severe acute respiratory syndrome. Lancet 361, 1773-1778.
10. Peiris, J. S., Chu, C. M., Cheng, V. C., et al. (HKU/UCH SARS Study Group) (2003). Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 361, 1767-1772.
11. Mashall, E., and Enserink, M. (2004). Caution urged on SARS vaccines. Science 303, 944-946.
12. Bisht, H., Roberts, A., Vogel, L., et al. (2004). Severe acute respiratory syndrome Coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA 101, 6641-6646.
13. Bukreyev, A., Lamirande, E. W., Buchholz, U. J., et al. (2004). Mucosal immunization of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS Coronavirus spike protein for the prevention of SARS. Lancet 363, 2122-2127.
14. Yang, Z. Y., Kong, W. P., Huang, Y., et al. (2004). A DNA vaccine induces SARS Coronavirus neutralization and protective immunity in mice. Nature 428, 561-564.
15. Hogan, R. J., Gao, G., Rowe, T., et al. (2004). Resolution of primary severe acute respiratory syndrome-associated Coronavirus infection requires Statl. J. Virol. 78, 11416-11421.
16. Zhong, N. S., Zheng, B. J., Li, Y. M., et al. (2003). Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February 2003. Lancet 362, 1353-1358.
17. Subbarao, K., McAuliffe, J., Vogel, L., et al. (2004). Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome Coronavirus in the respiratory tract of mice. J. Virol. 78, 3572-3577.
18. Hensley, L. E., Fritz, L. E., Jahrling, P. B., Karp, C. L., Huggins, J. W., and Geisbert, T. W. (2004). Interferon-β 1a and SARS Coronavirus replication. Emerg. Infect. Dis. 10, 317-319.
19. Spiegel, M., Pichlmair, A., Muhlberger, E., Haller, O., and Weber, F. (2004). The antiviral effect of interferon-β against SARS-coronavirus is not mediated by MxA protein. J. Clin. Virol. 30, 211-213.
20. Sainz, B., Jr., Mossel, E. C., Peters, C. J., and Garry, R. F. (2004). Interferonbeta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated Coronavirus (SARS-CoV). Virology 329, 11-17.
21. Haagmans, B. L., Kuiken, T., Martina, B. E., et al. (2004). Pegylated interferon-α protects type 1 pneumocytes against SARS Coronavirus infection in macaques. Nat. Med. 10, 290-293.
22. Rowe, T., Gao, G., Hogan, R. J., et al. (2004). Macaque model for severe acute respiratory syndrome. J. Virol. 78, 11401-11404.
23. Qin, C., et al. (2004). Histological changes in SARS-CoV infected rhesus monkeys. Proc. Chinese Assoc. Experimental Animal Res., 38-45.
24. Wei, Q., et al. (2004). Virologie and serologic detection of SARS-CaV in infected rhesus monkey. Proc. Chinese Assoc. Experimental Animal Res., 46-48.
25. Chen, Z., Zhang, L., Qin, C., et al. (2005). Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome Coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region, J. Virol. 79, 2678-2688.
26. Qin, C., Wang, J., Wei, Q., et al. (2005). An animal model of SARS produced by infection of Macaca mulatta with SARS Coronavirus. J. Pathol. 206, 251-259.
27. Haasnoot, P. C., Cupac, D., and Berkhout, B. (2003). Inhibition of virus replication by RNA interference. J. Biomed. Sci. 10, 607-616.
28. Bitko, V., and Barik, S. (2001). Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 1, 34.
29. Zheng, B. J., Guan, Y., Tang, Q., et al. (2004). Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir. Ther. 9, 365-374.
30. Elmen, J., Wahlestedt, C., Brytting, M., Wahren, B., and Ljungberg, K. (2004). SARS virus inhibited by siRNA. Preclinica 2, 135-142.
31. Zhang, Y., Li, T., Fu, L., et al. (2004). Silencing SARS-CoV protein expression in cultured cells by RNA interference. FEBS Lett. 560, 141-146.
32. Zhang, R., Guo, Z., Lu, J., et al. (2003). Inhibiting severe acute respiratory syndrome-associated Coronavirus by small interfering RNA. Chin. Med. J. (Engl.) 116, 1262-1264.
33. Wang, Z., Ren, L., Zhao, X., et al. (2004). Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J. Virol. 78, 7523-7527.
34. Li, B. J., Tang, Q., Cheng, D., et al. (2005). Using siRNA in prophylactic and therapeutic regimens against SARS Coronavirus in Rhesus macaque. Nat. Med. 11, 944-951.
35. Bitko, V., Musiyenko, A., Shulyayeva, O., and Barik, S. (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11, 50-55.
36. Tompkins, S. M., Lo, C. Y., Tumpey, T. M., and Epstein, S. L. (2004). Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101, 8682-8686.
37. Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H. N., and Chen, J. (2004). Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101, 8676-8681.
38. Trubetskoy, V. S., Wong, S. C., Subbotin, V., et al. (2003). Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Ther. 10, 261-271.
39. Boeckle, S., von Gersdorff, K., van der Piepen, S., Culmsee, C., Wagner, E., and Ogris, M. (2004). Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J. Gene Med. 6, 1102-1111.
40. Delepine, P., Guillaume, C., Montier, T., et al. (2003). Biodistribution study of phosphonolipids: A class of non-viral vectors efficient in mice lung-directed gene transfer. J. Gene Med. 5, 600-608.
41. Ghanayem, N. S., Yee, L., Nelson, T., et al. (2001). Stability of dopamine and epinephrine solutions up to 84 hours. Pediatr. Crit. Care Med. 2, 315-317.
42. Thomas, N. J., Hollenbeak, C. S., Lucking, S. E., and Willson, D. F. (2005). Cost-effectiveness of exogenous surfactant therapy in pediatric patients with acute hypoxemic respiratory failure. Pediatr. Crit. Care Med. 6, 160-165.
43. Ennist, D., et al. (2000). Method of achieving persistent transgene expression. U.S. patent application 20030148975, PCT/EP00/13297.
44. Massaro, D., Massaro, G. D., and Clerch, L. B. (2004). Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 287, 1066-1070.
45. Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., and Williams, B. R. (2003). Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839.
46. Kariko, K., Bhuyan, P., Capodici, J., and Weissman, D. (2004). Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-like receptor 3. J. Immunol. 172, 6545-6549.
47. Heidel, J. D., Hu, S., Liu, X. F., Triche, T. J., and Davis, M. E. (2004). Lack of interferon response in animals to naked siRNAs. Nat. Biotechnol. 22, 1579-1582.
48. Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., and MacLachlan, I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-562.
49. Hornung, V., Guenthner-Biller, M., Bourquin, C., et al. (2005). Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270.
50. Bonnard, E., Mazarguil, H., and Zajac, J. M. (2002). Peptide nucleic acids targeted to the mouse proNPFF(A) reveal an endogenous opioid tonus. Peptides 23, 1107-1113.
51. Semizarov, D., Frost, L., Sarthy, A., Kroeger, P., Halbert, D. N., and Fesik, S. W. (2003). Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. USA 100, 6347-6352.
52. Chi, J. T., Chang, H. Y., Wang, N. N., Chang, D. S., Dunphy, N., and Brown, P. O. (2003). Genomewide view of gene silencing by small interfering RNAs. Proc. Natl. Acad. Sci. USA 100, 6364-6369.
53. Jackson, A. L., Bartz, S. R., Schelter, J., et al. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637.
54. Ware, L. B., and Matthay, M. A. (2000). The acute respiratory distress syndrome. N. Engl. J. Med. 342, 1334-1349.
55. Yuen, K. Y., Chan, P. K., Peiris, M., et al. (1998). Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351, 467-471.
56. Huang, K. J., Su, I. J., Theron, M., et al. (2005). An interferon-gamma-related cytokine storm in SARS patients. J. Med. Virol. 75, 185-194.
57. Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., and Doerr, H. W. (2003). Treatment of SARS with human interferons. Lancet 362, 293-294.